Literature DB >> 7678053

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

I Bongarzone1, N Monzini, M G Borrello, C Carcano, G Ferraresi, E Arighi, P Mondellini, G Della Porta, M A Pierotti.   

Abstract

The ret oncogene frequently has been found activated in papillary thyroid carcinomas. A previous characterization of ret activation revealed recombination of its tyrosine kinase domain and sequences derived from an uncharacterized locus (D10S170). The mechanism leading to this recombination was identified as a paracentric inversion of the long arm of chromosome 10, inv(10)(q11.2q21), with the breakpoints occurring where ret and D10S170 were mapped. To further characterize the activation of ret in papillary thyroid carcinomas, we have now isolated and sequenced a second type of ret oncogenic rearrangement not involving the D10S170 locus. The nucleotide sequence indicated that the transforming activity was created by the fusion of the ret tyrosine kinase domain with part of the RI alpha regulatory subunit of protein kinase A (PKA). This is the first example of an oncogenic activity involving a PKA gene. PKA is the main intracellular cyclic AMP receptor, and its RI alpha subunit gene is located on chromosome 17q. RI alpha-ret transcripts encode two isoforms of the chimeric protein (p76 and p81), which display constitutive tyrosine phosphorylation as well as a tyrosine kinase enzymatic activity. Under nonreducing conditions, both isoforms are found in a dimeric configuration because of both homo- and heterodimer formation. Thus, the in vivo activation of ret in human papillary thyroid carcinomas is provided by the fusion of its tyrosine kinase domain with different genes and can be mediated by different mechanisms of gene rearrangement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678053      PMCID: PMC358915          DOI: 10.1128/mcb.13.1.358-366.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  27 in total

1.  Alkaline phosphatase: affinity chromatography and inhibition by phosphonic acids.

Authors:  M Landt; S C Boltz; L G Butler
Journal:  Biochemistry       Date:  1978-03-07       Impact factor: 3.162

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

6.  Phosphotyrosine-containing proteins isolated by affinity chromatography with antibodies to a synthetic hapten.

Authors:  A H Ross; D Baltimore; H N Eisen
Journal:  Nature       Date:  1981-12-17       Impact factor: 49.962

7.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

Review 8.  The cyclic AMP-mediated stimulation of cell proliferation.

Authors:  J E Dumont; J C Jauniaux; P P Roger
Journal:  Trends Biochem Sci       Date:  1989-02       Impact factor: 13.807

9.  Interchain disulfide bonding in the regulatory subunit of cAMP-dependent protein kinase I.

Authors:  S K Zick; S S Taylor
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

10.  Receptor for bombesin with associated tyrosine kinase activity.

Authors:  D M Cirillo; G Gaudino; L Naldini; P M Comoglio
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

View more
  49 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  Novel sequence variants of the genes associated with the multiple endocrine neoplasia syndromes 1 and 2. analysis by an "in silico approach.".

Authors:  P Igaz; A Patócs; K Rácz
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

3.  Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice.

Authors:  C Gestblom; D A Sweetser; B Doggett; R P Kapur
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.

Authors:  M K Webster; D J Donoghue
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

5.  Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Ya'an Kang; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

6.  Signaling through dynamic linkers as revealed by PKA.

Authors:  Madoka Akimoto; Rajeevan Selvaratnam; E Tyler McNicholl; Geeta Verma; Susan S Taylor; Giuseppe Melacini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-14       Impact factor: 11.205

7.  Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.

Authors:  M P Cosma; M Cardone; F Carlomagno; V Colantuoni
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 8.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

9.  Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.

Authors:  K Durick; G N Gill; S S Taylor
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

10.  High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Authors:  Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.